Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candin for Common Warts
NCT05889845Phase 3Completed
- Sponsor
- Nielsen BioSciences, Inc.
- Start
- Jan 2025
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in common warts comparing Candin treatment with Placebo (2 arms). Primary endpoint: Number of participants with complete resolution of the treatment wart. Started Jan 2025; status: completed.
02
Drugs
candida albicans extract
03
Conditions
common warts
Beyond the preview
Go deeper on NCT05889845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889845.